Cover Image
Market Research Report

Th17 Inflammatory Pathway Therapeutics

Published by Greystone Research Associates Product code 892533
Published Content info
Delivery time: 1-2 business days
Price
Back to Top
Th17 Inflammatory Pathway Therapeutics
Published: July 22, 2019 Content info:
Description

Immune-mediated inflammatory diseases (IMIDs) is a term that encompasses a number of common, chronic and complex disorders, characterized by a dysregulation of the normal immune response which leads to inflammation in target organs and, usually, systemic effects as well. Examples include type 1 diabetes (T1D), Crohn's disease (CD), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), multiple sclerosis (MS) and psoriasis. This report examines the therapeutic products and strategies that are being employed to improve outcomes by modulating the intracellular production of inflammatory mediators.

What You Will Learn

  • What are the immune factors in the Th17 helper cell pathway that are responsible for immune mediated inflammatory Autoimmune Diseases?
  • What are the inflammatory-mediated ligands, receptors, signaling proteins and transcription factors that represent druggable targets in the Th17 helper cell?
  • What are the major factors driving the high level of development activity in immune mediated inflammatory diseases?
  • What is the size of the market today, who are the market share leaders, and what will the market share be in 2022?
  • What are the significant economic, technology, and regulatory factors affecting the market for immune therapeutics
Table of Contents
Product Code: JPT456K

Executive Summary

The Th17 Pathway

Th17 Inflammatory Pathway Cascade Targets

Interleukin 6 (IL-6)

  • Approved Drugs
  • Development-stage Drugs

Interleukin IL-6R

  • Approved Drugs
  • Development-stage Drugs

Janus Kinase/Tyrosine Kinase Inhibitors

  • Approved Drugs
  • Development-stage Drugs

Signaling Proteins

  • Signal Transducer and Activator of Transcription (STAT)

Interleukin-21 (IL-21)

Interleukin-21R (IL-21R)

Interleukin-23 (IL-23)

  • Approved Drugs
  • Development-stage Drugs

Interleukin-23R (IL-23R)

Interleukin-17A (IL-17A)

  • Approved Drugs

Interleukin-17C (IL-17C)

  • Development-stage Drugs

Interleukin 17A/17F

  • Development-stage Drugs

Interleukin-17RA (IL-17RA)

  • Approved Drugs

Transforming Growth Factor-β RI/RII (TGF-β RI/RII)

  • Development-stage Drugs

Retinoic acid-related orphan receptor (RORyt)

  • Development-stage Drugs

Interleukin 17

  • Development-stage Drugs

Interleukin-22 (IL-22)

Market Status

Market Size

Competitive Landscape

Th17 Pathway Mediated Inflammatory Diseases

  • Addressable Market
  • Competitive Landscape

Profiles of Market Participants

Back to Top